Hologic adds SARS-CoV-2 test to global testing project

LabPulse.com staff writers
Jan 4, 2022
2021 10 08 23 57 9144 Earth Hands Globe World 400

Hologic has added its Aptima SARS-CoV-2 assay to the company's Global Access Initiative (GAI), a program that is intended to expand access to critical diagnostic testing in resource-limited countries.

Hologic launched GAI at the 2018 International AIDS Conference as an initiative to offer an all-inclusive pricing structure with no upfront cost or capital expenditure. In addition to the SARS-CoV-2 assay, the company offers other tests in the initiative, including tests for HIV-1, hepatitis B and C, and HPV.

The Aptima assay is available through the World Health Organization Diagnostics Consortium, which helps middle- and low-income countries secure critical quantities of diagnostic tests.

Latest in AIDS
2022 01 26 06 58 5027 Women Laboratory 400
Quest Diagnostics launches monkeypox virus testing
July 12, 2022
2020 03 03 23 13 0226 Hepatitis C Virus 400
Co-Diagnostics joint venture approved for HCV test in India
April 18, 2022
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2021 05 21 20 55 6118 Breast Cancer 3 D 400
New biosensor aids early diagnosis of breast cancer
May 20, 2021
Related Stories
2022 04 29 18 14 4601 Hologic Rsna 2019 400
Influenza
Hologic launches respiratory assays in Europe
2022 04 29 18 14 4601 Hologic Rsna 2019 400
Cytomegalovirus
FDA clears Hologic's assay for human cytomegalovirus
2022 04 29 18 14 4601 Hologic Rsna 2019 400
Infectious
Lower sales of COVID tests drag down Hologic Q2 revenues
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in AIDS
Quest Diagnostics launches monkeypox virus testing
By LabPulse.com staff writers
The service will be available nationwide, with the exception of New York state, where Quest anticipates it will be available later if the New York Department of Health approves the laboratory-developed test.
July 12, 2022
2022 01 26 06 58 5027 Women Laboratory 400
Co-Diagnostics joint venture approved for HCV test in India
By LabPulse.com staff writers
Co-Diagnostics said its joint venture in India, CoSara Diagnostics, has received clearance to manufacture and sell its Saraq Hepatitis C (HCV) Viral Load Kit as an in vitro diagnostic.
April 18, 2022
2020 03 03 23 13 0226 Hepatitis C Virus 400
Whole-genome sequencing aids diagnosis of rare diseases
By Rebekah Moan
In a pilot study, the genes of nearly 5,000 people with rare, undiagnosed diseases were analyzed by researchers from Genomics England and Queen Mary University of London partnered with the National Institute for Health Research BioResource. The group claimed the project was the first to analyze the diagnostic and clinical effect of whole-genome sequencing for a wide range of rare diseases within a national healthcare system -- in this instance, the U.K. National Health Service (NHS).
November 10, 2021
2021 11 10 18 26 8156 Science Genome Sequence Dna Map 400
New biosensor aids early diagnosis of breast cancer
By LabPulse.com staff writers
In a study published in ACS Sensors, a research team led by Dr. Ramón Martínez Máñez from Valencia Polytechnic University noted that mammography is the gold standard for breast cancer detection, but radiation and lower sensitivity and specificity in young women with dense breast tissue are drawbacks to the imaging technology.
May 20, 2021
2021 05 21 20 55 6118 Breast Cancer 3 D 400
Hologic wraps up Biotheranostics acquisition
By LabPulse.com staff writers
Hologic had unveiled plans to acquire Biotheranostics for $230 million in January. Through the deal, Hologic gains two laboratory-developed tests -- the Breast Cancer Index, which predicts effects of endocrine therapy in breast cancer patients and CancerType ID, which aids in the molecular characterization of uncertain and unknown cancers.
February 21, 2021
2020 01 02 21 24 9838 Hologic Rsna 2019 400
Patients approve of medical screening at dental offices
By Emily Hayes
In the survey of 573 people, 89% were willing to have their dentist take their blood pressure and 82.9% were willing to undergo lab investigations for medical conditions, researchers from Saudi Arabia reported in a paper published February 2 in the open-access journal Dovepress.
February 4, 2021
2018 10 11 20 26 7990 Patient Woman Doctor 400
BioMerieux debuts clinical informatics software
By LabPulse.com staff writers
The Clarion software-as-a-service tool aids antimicrobial stewardship programs at labs and hospitals. The software provides critical infectious disease data and increased visibility for the value of diagnostics, the company noted.
November 22, 2020
2019 08 20 21 56 4986 Biomerieux Aacc 2019 400
Rite Aid adds 161 COVID-19 testing sites
By LabPulse.com staff writers
The new sites will be in California, Oregon, Washington, Idaho, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, and Virginia. These new locations bring Rite Aid's total testing sites to 258.
July 14, 2020
2020 06 15 18 14 5259 Swab Sample Collection 400
Rite Aid to nearly triple testing sites for COVID-19
By LabPulse.com staff writers
Beginning on May 11, the retailer will add 46 no-charge testing sites, including many drive-through testing sites. The additional sites raise the number of Rite Aid testing locations to 71 stores in 12 U.S. states.
May 7, 2020
2020 04 30 22 13 6857 Coronavirus Swab Ppe 400
MycoDart Aspergillus DNA test gets reimbursement code
By LabPulse.com staff writers
The Carrollton, TX-based company develops tests for people who need rapid detection of infections, such as patients with cancer or AIDS or those who are undergoing transplants. The accuracy of MycoDart's DNA test is up to 95% and results are available within hours, compared with 50% accuracy and results in days for blood cultures, the company noted in a statement about the CPT code.
August 12, 2019
2019 08 13 00 44 4010 Aspergillus Fungus Photomicrograph 400
Page 1 of 1